Cédric Panje1, Nikolaus Andratschke1, Thomas B Brunner2, Maximilian Niyazi3, Matthias Guckenberger4. 1. Department of Radiation Oncology, Zurich University Hospital, Rämistrasse 100, 8091, Zurich, Switzerland. 2. Department of Radiation Oncology, Freiburg University Hospital, Freiburg, Germany. 3. Department of Radiation Oncology, University of Munich, Munich, Germany. 4. Department of Radiation Oncology, Zurich University Hospital, Rämistrasse 100, 8091, Zurich, Switzerland. matthias.guckenberger@usz.ch.
Abstract
PURPOSE: This report of the Working Group on Stereotactic Radiotherapy of the German Society of Radiation Oncology (DEGRO) aims to provide a literature review and practice recommendations for stereotactic body radiotherapy (SBRT) of primary renal cell cancer and primary pancreatic cancer. METHODS: A literature search on SBRT for both renal cancer and pancreatic cancer was performed with focus on prospective trials and technical aspects for clinical implementation. RESULTS: Data on renal and pancreatic SBRT are limited, but show promising rates of local control for both treatment sites. For pancreatic cancer, fractionated SBRT should be preferred to single-dose treatment to reduce the risk of gastrointestinal toxicity. Motion-compensation strategies and image guidance are paramount for safe SBRT delivery in both tumor entities. CONCLUSION: SBRT for renal cancer and pancreatic cancer have been successfully evaluated in phase I and phase II trials. Pancreatic SBRT should be practiced carefully and only within prospective protocols due to the risk of severe gastrointestinal toxicity. SBRT for primary renal cell cancer appears a viable option for medically inoperable patients but future research needs to better define patient selection criteria and the detailed practice of SBRT.
PURPOSE: This report of the Working Group on Stereotactic Radiotherapy of the German Society of Radiation Oncology (DEGRO) aims to provide a literature review and practice recommendations for stereotactic body radiotherapy (SBRT) of primary renal cell cancer and primary pancreatic cancer. METHODS: A literature search on SBRT for both renal cancer and pancreatic cancer was performed with focus on prospective trials and technical aspects for clinical implementation. RESULTS: Data on renal and pancreatic SBRT are limited, but show promising rates of local control for both treatment sites. For pancreatic cancer, fractionated SBRT should be preferred to single-dose treatment to reduce the risk of gastrointestinal toxicity. Motion-compensation strategies and image guidance are paramount for safe SBRT delivery in both tumor entities. CONCLUSION: SBRT for renal cancer and pancreatic cancer have been successfully evaluated in phase I and phase II trials. Pancreatic SBRT should be practiced carefully and only within prospective protocols due to the risk of severe gastrointestinal toxicity. SBRT for primary renal cell cancer appears a viable option for medically inoperable patients but future research needs to better define patient selection criteria and the detailed practice of SBRT.
Authors: Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase Journal: Radiother Oncol Date: 2005-07 Impact factor: 6.280
Authors: Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2009-12-08 Impact factor: 66.675
Authors: Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-27 Impact factor: 7.038
Authors: Aaron T Wild; Susan M Hiniker; Daniel T Chang; Phuoc T Tran; Mouen A Khashab; Maneesha R Limaye; Daniel A Laheru; Dung T Le; Rachit Kumar; Jonathan S Pai; Blaire Hargens; Andrew B Sharabi; Eun Ji Shin; Lei Zheng; Timothy M Pawlik; Christopher L Wolfgang; Albert C Koong; Joseph M Herman Journal: J Gastrointest Oncol Date: 2013-12
Authors: Avani S Dholakia; Rachit Kumar; Siva P Raman; Joseph A Moore; Susannah Ellsworth; Todd McNutt; Daniel A Laheru; Elizabeth Jaffee; John L Cameron; Phuoc T Tran; Robert F Hobbs; Christopher L Wolfgang; Joseph M Herman Journal: Int J Radiat Oncol Biol Phys Date: 2013-12-01 Impact factor: 7.038
Authors: Aaron T Wild; Joseph M Herman; Avani S Dholakia; Shalini Moningi; Yao Lu; Lauren M Rosati; Amy Hacker-Prietz; Ryan K Assadi; Ali M Saeed; Timothy M Pawlik; Elizabeth M Jaffee; Daniel A Laheru; Phuoc T Tran; Matthew J Weiss; Christopher L Wolfgang; Eric Ford; Stuart A Grossman; Xiaobu Ye; Susannah G Ellsworth Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-01 Impact factor: 7.038
Authors: Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: M Guckenberger; N Andratschke; H Alheit; R Holy; C Moustakis; U Nestle; O Sauer Journal: Strahlenther Onkol Date: 2013-09-21 Impact factor: 3.621
Authors: S Dobiasch; S Kampfer; R Burkhardt; D Schilling; T E Schmid; J J Wilkens; S E Combs Journal: Strahlenther Onkol Date: 2017-08-14 Impact factor: 3.621
Authors: R Damm; T Streitparth; P Hass; M Seidensticker; C Heinze; M Powerski; J J Wendler; U B Liehr; K Mohnike; M Pech; J Ricke Journal: Strahlenther Onkol Date: 2019-07-25 Impact factor: 3.621
Authors: Morgan Michalet; Karl Bordeau; Marie Cantaloube; Simon Valdenaire; Pierre Debuire; Sebastien Simeon; Fabienne Portales; Roxana Draghici; Marc Ychou; Eric Assenat; Marie Dupuy; Sophie Gourgou; Pierre-Emmanuel Colombo; Sebastien Carrere; François-Regis Souche; Norbert Aillères; Pascal Fenoglietto; David Azria; Olivier Riou Journal: Front Oncol Date: 2022-03-09 Impact factor: 6.244